Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI

Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study

(2017) Lasse Hjort Jakobsen et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

The Danish National Lymphoma Registry: Coverage and Data Quality

(2016) Bente Arboe et al.   PLoS One

Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma

(2015) Matthew J. Maurer et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma

(2015) Tarec Christoffer El-Galaly et al.   AMERICAN JOURNAL OF HEMATOLOGY

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) H. Tilly et al.   ANNALS OF ONCOLOGY

A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry

(2015) Anne O. Gang et al.   LEUKEMIA & LYMPHOMA

Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era

(2015) Chieh-Sheng Lu et al.   LEUKEMIA & LYMPHOMA

Evaluating Random Forests for Survival Analysis Using Prediction Error Curves

(2015) Ulla B. Mogensen et al.   Journal of Statistical Software

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

(2014) Laurie H. Sehn et al.   BLOOD

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry

(2014) F. Ellin et al.   BLOOD

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

(2014) Matthew J. Maurer et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas

(2013) Raju K. Pillai et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

(2013) Z. Zhou et al.   BLOOD

Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks

(2013) Paul Blanche et al.   STATISTICS IN MEDICINE

Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era

(2011) Hiroyuki Takahashi et al.   CANCER

To Explain or to Predict?

(2011) Galit Shmueli   STATISTICAL SCIENCE

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Random survival forests

(2008) Hemant Ishwaran et al.   Annals of Applied Statistics